MEDICARE IS FINALLY COVERING GLP-1’s for WEIGHT LOSS
Medicare Is Finally Covering GLP‑1s for Weight Loss — Here’s What You Actually Need to Know
Something significant is happening on July 1, 2026. For the first time in Medicare’s history, the program is covering GLP-1 medications for obesity — not just for diabetes, not just for cardiovascular disease, but specifically for weight loss.
If you or someone you know is on Medicare and has been priced out of Wegovy, Zepbound, or other GLP-1s, this matters. But before you assume your coverage problem is solved, there are critical gaps you need to understand.
What Is the Medicare GLP-1 Bridge?
The Medicare GLP-1 Bridge is a federal demonstration program created by CMS. Starting July 1, 2026, Medicare Part D beneficiaries who meet specific clinical criteria can access Wegovy, Foundayo, or Zepbound for obesity treatment at a $50 per month copayment.
The program runs through December 31, 2027 — extended from its original end date of December 2026.
Medicare covers roughly 67 million Americans and has been legally prohibited from covering weight loss drugs since 2003. This is a genuine policy shift — and for many patients, potentially transformative access to medications they previously couldn’t afford.
- Patient cost: $50/month copay
- Government’s negotiated price from manufacturers: $245/month
- Eligibility: Prior authorization required
- Covered medications: Wegovy, Foundayo, Zepbound KwikPen
- Program runs: July 1, 2026 → December 31, 2027
The Three Gaps Nobody Is Talking About
Gap 1 — The Low-Income Penalty
Medicare’s Low Income Subsidy (LIS) normally reduces or eliminates drug copayments for low-income seniors. That subsidy does not apply to the GLP-1 Bridge. A qualifying Medicare patient on fixed income still faces $50/month with no reduction — effectively excluding many who medically qualify.
Gap 2 — The Clock Is Ticking
The BALANCE Model — the permanent GLP-1 coverage program meant to replace the Bridge beginning in 2027 — is indefinitely delayed. In April 2026, CMS announced not enough Medicare Part D plans signed up to participate. There is currently no confirmed coverage mechanism after December 2027. Stopping a GLP-1 after sustained use typically results in significant weight regain.
Gap 3 — Not Everyone Qualifies
Prior authorization requires clinical documentation and attestation from a provider. Patients who are denied will need to appeal or find alternative access. Without a provider who understands the Bridge process and submits correctly, approval is not guaranteed.
What If You Don’t Qualify?
For patients who don’t qualify for the Bridge, or for whom $50/month is still unaffordable, direct-pay GLP-1 programs offer a clear alternative path.
At Monday Medical, our GLP-1 programs start at $250/month for semaglutide and $350/month for tirzepatide — comparable to or lower than the Bridge copay, without the prior authorization complexity or the 2027 expiration risk.
Every Monday Medical GLP-1 patient receives ongoing clinical oversight, regular labs, protocol adjustments, and direct provider access. The medication is only part of the protocol.
Whether you want help qualifying for the Medicare GLP-1 Bridge or you need a long-term program not subject to a government expiration date — that’s exactly what Monday Medical is built for. Our providers know the Bridge process and can also offer a direct-pay alternative at comparable pricing with better, more personalized care.
